Raymond James analyst Steven Seedhouse raised the firm's price target on Mirum Pharmaceuticals to $69 from $51 and keeps a Strong Buy rating on the shares. The approval of Livmarli, the first and only approved drug for cholestatic pruritus in Alagille Syndrome, comes with ~30% higher pricing than Seedhouse previously modeled, the analyst tells investors in a research note. The market's relatively muted reaction to approval despite overly discounting for regulatory risk heading into approval provides an opportunity to buy now, Seedhouse contends.
Submitted September 30, 2021 at 08:16AM by stillness0072 https://ift.tt/39OZ8bJ
